Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase IIIb open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when given as a catch-up immunization in children older than 7 months of age or given as a 3-dose primary immunization in children before 6 months of age.

    Summary
    EudraCT number
    		 2006-001482-42
    Trial protocol
    		 FI  
    Global end of trial date
    15 Nov 2007

    Results information
    Results version number
    		 v2
    This version publication date
    27 Feb 2016
    First version publication date
    14 Jun 2015
    Other versions
    		 v1 , v3
    Version creation reason
    • New data added to full data set
    Data for secondary endpoints have been added.

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    107058
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT00345358
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l’Institut 89, Rixensart, Belgium, B-1330
    Public contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Apr 2008
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    15 Nov 2007
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when given as a catch-up immunization in children older than 7 months of age (three age-groups with different schedules).
    Protection of trial subjects
    All vaccines were observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for up to 31 days for adverse events after the last vaccination/product administration and during the entire study period for serious adverse events.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    18 Sep 2006
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Finland: 600
    Worldwide total number of subjects
    600
    EEA total number of subjects
    600
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    450
    Children (2-11 years)
    150
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 The study included a primary (PRI) phase (all groups) and a booster (BST) phase (only 10Pn <6M and 10Pn 7-11M groups).

    Pre-assignment
    Screening details
    		 At screening the following was performed: informed consent was obtained from & signed by subjects’ parents/guardians, check for inclusion/exclusion criteria and precautions was performed as regards contraindications to vaccination, and medical history of subjects was collected. Subjects’ pre-vaccination body temperature was evaluated.

    Period 1
    Period 1 title
    Primary Vaccination Phase
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 10Pn <6M Group
    Arm description
    		 This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of 10Pn-PD-DiT (or 10Pn) vaccine co-administered with InfanrixTM IPV/Hib (DTPa-IPV/Hib) at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (10Pn-PD-DiT) or the left (DTPa-IPV/Hib) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
    Arm type
    		 Experimental

    Investigational medicinal product name
    10-valent streptococcus pneumoniae conjugate vaccine
    Investigational medicinal product code
    Other name
    10Pn-PD-DiT, 10Pn
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses administered at 3, 4 and 5 months of age followed by a booster dose at 12-15 months of age, all injected intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Investigational medicinal product name
    Infanrix-Polio+Hib
    Investigational medicinal product code
    Other name
    InfanrixTM IPV/Hib, DTPa-IPV/Hib
    Pharmaceutical forms
    Powder and solvent for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses administered at 3, 4 and 5 months of age followed by a booster dose at 12-15 months of age, all injected intramuscularly in the left right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Arm title
    		 10Pn 7-11M Group
    Arm description
    		 This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
    Arm type
    		 Experimental

    Investigational medicinal product name
    10-valent streptococcus pneumoniae conjugate vaccine
    Investigational medicinal product code
    Other name
    10Pn-PD-DiT, 10Pn
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    2 doses, one first dose at enrolment followed by a second dose one month later, followed by a booster dose at 12-15 months of age., injected intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Arm title
    		 10Pn 12-23M Group
    Arm description
    		 This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose 2 months later. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
    Arm type
    		 Experimental

    Investigational medicinal product name
    IMP Name 10-valent streptococcus pneumoniae conjugate vaccine
    Investigational medicinal product code
    Other name
    10Pn-PD-DiT, 10Pn
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose 2 months later, injected intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Arm title
    		 10Pn >=24M Group
    Arm description
    		 This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of 10Pn-PD-DiT (10Pn). The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
    Arm type
    		 Experimental

    Investigational medicinal product name
    10-valent streptococcus pneumoniae conjugate vaccine
    Investigational medicinal product code
    Other name
    10Pn-PD-DiT, 10Pn
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    One dose administered when subject’s age was between 24 months (inclusive) to 5 years of age (inclusive) at vaccination, injected intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Number of subjects in period 1
    		10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Started
    150
    150
    150
    150
    Completed
    145
    146
    142
    148
    Not completed
    5
    4
    8
    2
         Consent withdrawn by subject
    1
    2
    4
    -
         Adverse event, non-fatal
    3
    1
    1
    -
         Other reason (unspecified)
    -
    1
    1
    -
         Lost to follow-up
    1
    -
    2
    2
    Period 2
    Period 2 title
    Booster Vaccination Phase
    Is this the baseline period?
    		 No
    Allocation method
    Randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 10Pn <6M Group
    Arm description
    		 This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of 10Pn-PD-DiT (or 10Pn) vaccine co-administered with InfanrixTM IPV/Hib (DTPa-IPV/Hib) at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (10Pn-PD-DiT) or the left (DTPa-IPV/Hib) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
    Arm type
    		 Experimental

    Investigational medicinal product name
    10-valent streptococcus pneumoniae conjugate vaccine
    Investigational medicinal product code
    Other name
    10Pn-PD-DiT, 10Pn
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses administered at 3, 4 and 5 months of age followed by a booster dose at 12-15 months of age, all injected intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Investigational medicinal product name
    Infanrix-Polio+Hib
    Investigational medicinal product code
    Other name
    InfanrixTM IPV/Hib, DTPa-IPV/Hib
    Pharmaceutical forms
    Powder and solvent for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses administered at 3, 4 and 5 months of age followed by a booster dose at 12-15 months of age, all injected intramuscularly in the left right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Arm title
    		 10Pn 7-11M Group
    Arm description
    		 This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
    Arm type
    		 Experimental

    Investigational medicinal product name
    10-valent streptococcus pneumoniae conjugate vaccine
    Investigational medicinal product code
    Other name
    10Pn-PD-DiT, 10Pn
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    2 doses, one first dose at enrolment followed by a second dose one month later, followed by a booster dose at 12-15 months of age., injected intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Number of subjects in period 2 [1]
    		10Pn <6M Group 10Pn 7-11M Group
    Started
    145
    145
    Completed
    141
    145
    Not completed
    4
    0
         Consent withdrawn by subject
    1
    -
         Lost to follow-up
    3
    -
    Notes
    [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: One subject from the 10Pn 7-11M Group was not included in the Booster Phase of the study for not having received the booster vaccination dose.

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    10Pn <6M Group
    Reporting group description
    		 This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of 10Pn-PD-DiT (or 10Pn) vaccine co-administered with InfanrixTM IPV/Hib (DTPa-IPV/Hib) at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (10Pn-PD-DiT) or the left (DTPa-IPV/Hib) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn 7-11M Group
    Reporting group description
    		 This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn 12-23M Group
    Reporting group description
    		 This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose 2 months later. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn >=24M Group
    Reporting group description
    		 This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of 10Pn-PD-DiT (10Pn). The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group Total
    Number of subjects
    		 150 150 150 150 600
    Age categorical
    Units: Subjects
        In utero
    		 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0
        Newborns (0-27 days)
    		 0
        Infants and toddlers (28 days-23 months)
    		 0
        Children (2-11 years)
    		 0
        Adolescents (12-17 years)
    		 0
        Adults (18-64 years)
    		 0
        From 65-84 years
    		 0
        85 years and over
    		 0
    Age continuous
    Units: months
        arithmetic mean (standard deviation)
    		 10.8 ± 1.09 8.3 ± 1.2 17.9 ± 3.19 36.6 ± 11.87 -
    Gender categorical
    Units: Subjects
        Female
    		 66 68 76 72 282
        Male
    		 84 82 74 78 318

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    10Pn <6M Group
    Reporting group description
    		 This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of 10Pn-PD-DiT (or 10Pn) vaccine co-administered with InfanrixTM IPV/Hib (DTPa-IPV/Hib) at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (10Pn-PD-DiT) or the left (DTPa-IPV/Hib) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn 7-11M Group
    Reporting group description
    		 This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn 12-23M Group
    Reporting group description
    		 This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose 2 months later. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn >=24M Group
    Reporting group description
    		 This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of 10Pn-PD-DiT (10Pn). The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
    Reporting group title
    10Pn <6M Group
    Reporting group description
    		 This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of 10Pn-PD-DiT (or 10Pn) vaccine co-administered with InfanrixTM IPV/Hib (DTPa-IPV/Hib) at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (10Pn-PD-DiT) or the left (DTPa-IPV/Hib) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn 7-11M Group
    Reporting group description
    		 This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Primary: Number of subjects with anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations >= 0.20 microgram per milliliter (µg/mL). (Primary/full vaccination)

    		 Close Top of page
    End point title
    		 Number of subjects with anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations >= 0.20 microgram per milliliter (µg/mL). (Primary/full vaccination) [1]
    End point description
    Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations were assessed by 22F-inhibition Enzyme-Linked Immuno-Sorbent Assay (ELISA) method. The >=0.20 microgram per milliliter (microg/mL) cut-off corresponded to the seroprotection cut-off as regards anti-pneumococcal serotypes antibody concentrations. Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microg/mL.
    End point type
    Primary
    End point timeframe
    At one month after primary (10Pn <6M & 10Pn 7-11M groups) or after the full (10Pn 12-23M & 10Pn >=24M groups) vaccination course with 10Pn, that is Month (M)3 for 10Pn <6M & 12-23M groups, M2 for 10Pn 711M Group, & M1 for 10Pn >=24M Group,
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    131
    135
    133
    140
    Units: Subjects
        Anti-1 (N=131; 135; 133; 140)
    128
    135
    132
    135
        Anti-4 (N=131; 135; 133; 140)
    128
    135
    133
    140
        Anti-5(N=131; 135; 133; 138)
    130
    134
    131
    135
        Anti-6B (N=131; 135; 133; 140)
    95
    69
    108
    96
        Anti-7F (N=131; 135; 133; 140)
    130
    135
    133
    140
        Anti-9V (N=131; 135; 133; 140)
    128
    129
    130
    132
        Anti-14 (N=131; 135; 133; 139)
    130
    132
    132
    127
        Anti-18C (N=131; 135; 133; 140)
    127
    135
    133
    140
        Anti-19F (N=130; 135; 133; 140)
    122
    129
    131
    140
        Anti-23F (N=131; 135; 133; 139)
    114
    95
    122
    93
    No statistical analyses for this end point

    Secondary: Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. (Primary/full vaccination)

    		 Close Top of page
    End point title
    		 Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. (Primary/full vaccination)
    End point description
    Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Seropositivity = Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥0.05 µg/mL.
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary (< 6 months and 7-11 months groups) or the full (12-23 months and >= 24 months groups) vaccination course, with 10Pn-PD-DiT vaccine.
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    131
    135
    133
    140
    Units: µg/mL
    geometric mean (confidence interval 95%)
        Anti-1 (N=131; 135; 133; 140)
    1.2 (1.02 to 1.42)
    1.19 (1.05 to 1.35)
    1.22 (1.06 to 1.4)
    0.77 (0.66 to 0.89)
        Anti-4 (N=131; 135; 133; 140)
    1.84 (1.57 to 2.15)
    3.47 (3.03 to 3.97)
    4.21 (3.77 to 4.69)
    5.72 (5 to 6.54)
        Anti-5(N=131; 135; 133; 138)
    2.04 (1.75 to 2.37)
    1.72 (1.51 to 1.96)
    1.8 (1.57 to 2.06)
    1.16 (0.99 to 1.36)
        Anti-6B (N=131; 135; 133; 140)
    0.37 (0.29 to 0.48)
    0.21 (0.16 to 0.26)
    0.53 (0.43 to 0.65)
    0.38 (0.3 to 0.47)
        Anti-7F (N=131; 135; 133; 140)
    2.03 (1.76 to 2.33)
    2.1 (1.83 to 2.41)
    3.62 (3.22 to 4.06)
    2.6 (2.25 to 3.01)
        Anti-9V (N=131; 135; 133; 140)
    1.33 (1.14 to 1.55)
    0.91 (0.78 to 1.07)
    1.5 (1.3 to 1.73)
    1.01 (0.84 to 1.22)
        Anti-14 (N=131; 135; 133; 139)
    3 (2.61 to 3.46)
    2.3 (1.95 to 2.72)
    4.24 (3.64 to 4.95)
    1.36 (1.06 to 1.74)
        Anti-18C (N=131; 135; 133; 140)
    1.84 (1.5 to 2.26)
    4.82 (4.14 to 5.61)
    9.2 (8.22 to 10.29)
    4.65 (4.06 to 5.31)
        Anti-19F (N=130; 135; 133; 140)
    1.61 (1.28 to 2.02)
    3.36 (2.68 to 4.2)
    5.45 (4.63 to 6.41)
    5.26 (4.34 to 6.39)
        Anti-23F (N=131; 135; 133; 139)
    0.62 (0.5 to 0.76)
    0.4 (0.32 to 0.5)
    0.88 (0.73 to 1.05)
    0.37 (0.3 to 0.47)
    No statistical analyses for this end point

    Secondary: Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A. (Primary/full vaccination)

    		 Close Top of page
    End point title
    		 Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A. (Primary/full vaccination)
    End point description
    Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 6A, 19A (ANTI-6A, -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Seropositivity = Anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 µg/mL.
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary (< 6 months and 7-11 months groups) or the full (12-23 months and >= 24 months groups) vaccination course, with 10Pn-PD-DiT vaccine.
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    132
    135
    133
    138
    Units: µg/mL
    geometric mean (confidence interval 95%)
        Anti-6A (N=132;135;133;138)
    0.1 (0.08 to 0.12)
    0.06 (0.05 to 0.08)
    0.23 (0.18 to 0.29)
    0.24 (0.19 to 0.31)
        Anti-19A (N=131;135;133;138)
    0.09 (0.07 to 0.11)
    0.12 (0.1 to 0.15)
    0.86 (0.71 to 1.05)
    0.65 (0.53 to 0.82)
    No statistical analyses for this end point

    Secondary: Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. (Primary/full vaccination)

    		 Close Top of page
    End point title
    		 Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. (Primary/full vaccination)
    End point description
    OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. Seropositivity = Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F >= 8. Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary (< 6 months and 7-11 months groups) or the full (12-23 months and >= 24 months groups) vaccination course, with 10Pn-PD-DiT vaccine.
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    44
    48
    51
    41
    Units: Titer
    geometric mean (confidence interval 95%)
        Opsono-1 (N=44;48;51;41)
    17.3 (10.9 to 27.5)
    14.8 (9.3 to 23.6)
    14.2 (9 to 22.4)
    17.5 (9.4 to 32.3)
        Opsono-4 (N=41;46;50;36)
    675.6 (475.4 to 960)
    524 (361.8 to 758.9)
    912.1 (617.8 to 1346.8)
    2227.6 (1694 to 2929.3)
        Opsono-5(N=42;46;50;39)
    52.6 (33.7 to 82.2)
    33.7 (21.4 to 53.3)
    47.5 (30.2 to 74.8)
    14.1 (9.1 to 22)
        Opsono-6B (N=38;45;49;34)
    296 (130.3 to 672.2)
    25.4 (11.1 to 58.4)
    304.3 (143.8 to 644.2)
    331.7 (99.1 to 1109.8)
        Opsono-7F (N=43;46;48;38)
    1775.1 (1057.8 to 2978.8)
    2342.5 (1555.2 to 3528.2)
    4164.2 (2840.4 to 6105)
    3282.2 (2105.1 to 5117.6)
        Opsono-9V (N=41;44;50;37)
    1281.1 (895 to 1833.7)
    2209.6 (1628.6 to 2997.8)
    3525.8 (2675.4 to 4646.4)
    4526 (3581.7 to 5719.3)
        Opsono-14 (N=42;48;51;40)
    1523.3 (1028.7 to 2255.6)
    1818.9 (1356.4 to 2439.2)
    2277.2 (1804.9 to 2873)
    1957.4 (1516.6 to 2526.3)
        Opsono-18C (N=41;46;51 ;38)
    181.8 (120.8 to 273.5)
    971.7 (723.2 to 1305.5)
    1765.3 (1330.5 to 2342.2)
    2051.4 (1558.3 to 2700.5)
        Opsono-19F (N=42;43;50;41)
    194.7 (101.7 to 372.7)
    225.6 (128.6 to 395.7)
    592.7 (367.3 to 956.4)
    634.3 (400.2 to 1005.4)
        Opsono-23F (N=41;45;49;41)
    925.8 (422.6 to 2028.3)
    561.1 (273.7 to 1150.4)
    1656.4 (1063.6 to 2579.6)
    1575.2 (802.6 to 3091.7)
    No statistical analyses for this end point

    Secondary: Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A. (Primary/full vaccination)

    		 Close Top of page
    End point title
    		 Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A. (Primary/full vaccination)
    End point description
    OPA titers against pneumococcal serotypes 6A, 19A (Opsono-6A, 19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. Opsonophagocytic activity against cross-reactive pneumococcal serotypes 6A and 19A >= 8. Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary (< 6 months and 7-11 months groups) or the full (12-23 months and >= 24 months groups) vaccination course, with 10Pn-PD-DiT vaccine.
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    43
    45
    50
    38
    Units: Titer
    geometric mean (confidence interval 95%)
        Opsono-6A (N=41;44;50;35)
    14.4 (7.5 to 27.6)
    39.1 (19 to 80.6)
    150.7 (80.7 to 281.3)
    324.6 (142.6 to 738.6)
        Opsono-19 (N=43;45;49;38)
    5.1 (3.9 to 6.6)
    6.1 (4.2 to 8.8)
    39.5 (19 to 81.9)
    31.8 (14.3 to 70.7)
    No statistical analyses for this end point

    Secondary: Antibody concentrations against protein D (anti-PD). (Primary/full vaccination)

    		 Close Top of page
    End point title
    		 Antibody concentrations against protein D (anti-PD). (Primary/full vaccination)
    End point description
    Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. Seropositivity = Anti-PD antibody concentrations >= 100 EL.U/mL. Antibody concentrations < 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary (< 6 months and 7-11 months groups) or the full (12-23 months and >= 24 months groups) vaccination course, with 10Pn-PD-DiT vaccine.
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    131
    135
    133
    139
    Units: EL.U/mL
    geometric mean (confidence interval 95%)
        Anti-PD [N=131;135;133;139]
    1637.7 (1430.9 to 1874.3)
    654.2 (577.7 to 741)
    660 (554.9 to 785.1)
    224.8 (185.2 to 272.7)
    No statistical analyses for this end point

    Secondary: Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations >= 0.20 µg/mL. (Booster vaccination)

    		 Close Top of page
    End point title
    		 Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations >= 0.20 µg/mL. (Booster vaccination)
    End point description
    Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations were assessed by 22F-inhibition Enzyme-Linked Immuno-Sorbent Assay (ELISA) method. The >=0.20 microgram per millilitre (microg/mL) cut-off corresponded to the seroprotection cut-off as regards anti-pneumococcal serotypes antibody concentrations. Seropositivity = Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥0.05 µg/mL.
    End point type
    Secondary
    End point timeframe
    Before and one month after the booster dose with 10Pn for the < 6 months and 7-11 months groups
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    140
    114
    Units: Subjects
        Anti-1, PRE(N=140;114)
    101
    102
        Anti-1, POST(N=137;114)
    137
    114
        Anti-4, PRE(N=140;114)
    119
    112
        Anti-4, POST(N=137;114)
    137
    114
        Anti-5, PRE(N=140;114)
    123
    110
        Anti-5, POST(N=137;114)
    136
    114
        Anti-6B, PRE(N=140;114)
    108
    97
        Anti-6B, POST(N=137;114)
    132
    110
        Anti-7F, PRE(N=140;114)
    132
    114
        Anti-7F, POST(N=137;114)
    137
    114
        Anti-9V, PRE(N=140;114)
    131
    108
        Anti-9V, POST(N=137;114)
    137
    114
        Anti-14, PRE(N=140;114)
    131
    113
        Anti-14, POST(N=137;114)
    137
    114
        Anti-18C, PRE(N=140;114)
    127
    114
        Anti-18C, POST(N=137;114)
    137
    114
        Anti-19F, PRE(N=140;114)
    114
    112
        Anti-19F, POST(N=137;114)
    134
    112
        Anti-23F, PRE(N=140;114)
    116
    98
        Anti-23F, POST(N=137;114)
    136
    110
    No statistical analyses for this end point

    Secondary: Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations. (Booster vaccination)

    		 Close Top of page
    End point title
    		 Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations. (Booster vaccination)
    End point description
    Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations were assessed by 22F-inhibition Enzyme-Linked Immuno-Sorbent Assay (ELISA) method. The >=0.20 microgram per millilitre (microg/mL) cut-off corresponded to the seroprotection cut-off as regards anti-pneumococcal serotypes antibody concentrations. Seropositivity status, defined as Anti-pneumococcal serotypes antibody concentrations >=0.05 µg/mL.
    End point type
    Secondary
    End point timeframe
    Before and one month after the booster dose with 10Pn for the < 6 months and 7-11 months groups
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    140
    141
    Units: µg/mL
    geometric mean (confidence interval 95%)
        Anti-1, PRE(N=140;114)
    0.29 (0.25 to 0.34)
    0.49 (0.43 to 0.57)
        Anti-1, POST(N=137;114)
    1.84 (1.59 to 2.12)
    1.77 (1.55 to 2.02)
        Anti-4, PRE(N=140;114)
    0.56 (0.48 to 0.66)
    1.35 (1.17 to 1.57)
        Anti-4, POST(N=137;114)
    2.98 (2.6 to 3.42)
    3.79 (3.27 to 4.4)
        Anti-5, PRE(N=140;114)
    0.51 (0.44 to 0.59)
    0.8 (0.7 to 0.93)
        Anti-5, POST(N=137;114)
    2.21 (1.94 to 2.53)
    2.88 (2.48 to 3.34)
        Anti-6B, PRE(N=140;114)
    0.41 (0.34 to 0.5)
    0.48 (0.4 to 0.58)
        Anti-6B, POST(N=137;114)
    1.62 (1.35 to 1.94)
    1.39 (1.14 to 1.69)
        Anti-7F, PRE(N=140;114)
    0.82 (0.72 to 0.94)
    1.58 (1.39 to 1.8)
        Anti-7F, POST(N=137;114)
    3.31 (2.92 to 3.74)
    3.73 (3.24 to 4.28)
        Anti-9V, PRE(N=140;114)
    0.85 (0.73 to 0.98)
    0.79 (0.67 to 0.93)
        Anti-9V, POST(N=137;114)
    3.41 (2.96 to 3.92)
    2.13 (1.82 to 2.5)
        Anti-14, PRE(N=140;114)
    1.03 (0.85 to 1.25)
    2.3 (1.97 to 2.68)
        Anti-14, POST(N=137;114)
    3.96 (3.39 to 4.62)
    5.41 (4.71 to 6.22)
        Anti-18C, PRE(N=140;114)
    0.62 (0.53 to 0.74)
    2.58 (2.2 to 3.04)
        Anti-18C, POST(N=137;114)
    5.28 (4.55 to 6.12)
    9.4 (8.04 to 10.98)
        Anti-19F, PRE(N=140;114)
    0.55 (0.44 to 0.7)
    1.99 (1.65 to 2.4)
        Anti-19F, POST(N=137;114)
    3.38 (2.81 to 4.06)
    5.71 (4.68 to 6.97)
        Anti-23F, PRE(N=140;114)
    0.48 (0.39 to 0.58)
    0.57 (0.46 to 0.7)
        Anti-23F, POST(N=137;114)
    2.76 (2.37 to 3.21)
    1.65 (1.33 to 2.03)
    No statistical analyses for this end point

    Secondary: Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A.(Booster vaccination)

    		 Close Top of page
    End point title
    		 Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A.(Booster vaccination)
    End point description
    Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 6A, 19A (ANTI-6A, -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL).Seropositivity = Anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 μg/mL.
    End point type
    Secondary
    End point timeframe
    Before and one month after the booster dose with 10Pn for the < 6 months and 7-11 months groups
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    140
    114
    Units: µg/mL
    geometric mean (confidence interval 95%)
        Anti-6A, PRE(N=140;114)
    0.15 (0.12 to 0.19)
    0.18 (0.14 to 0.23)
        Anti-6A, POST(N=137;114)
    0.52 (0.4 to 0.68)
    0.55 (0.42 to 0.73)
        Anti-19A, PRE(N=140;114)
    0.1 (0.09 to 0.13)
    0.26 (0.21 to 0.32)
        Anti-19A, POST(N=137;114)
    0.49 (0.39 to 0.61)
    0.99 (0.78 to 1.25)
    No statistical analyses for this end point

    Secondary: Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. (Booster vaccination)

    		 Close Top of page
    End point title
    		 Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. (Booster vaccination)
    End point description
    OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F >= 8. Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.
    End point type
    Secondary
    End point timeframe
    Before and one month after the booster dose with 10Pn for the < 6 months and 7-11 months groups
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    51
    40
    Units: Titer
    geometric mean (confidence interval 95%)
        Opsono-1, PRE(N=51;38)
    6 (4.5 to 8.1)
    9.9 (5.8 to 16.9)
        Opsono-1, POST(N=48;40)
    188.4 (103.6 to 342.5)
    234.1 (127.4 to 430.2)
        Opsono-4, PRE(N=45;37)
    22.2 (12.4 to 39.9)
    94 (47.7 to 185.2)
        Opsono-4, POST(N=48;38)
    1486.3 (1138 to 1941)
    978.3 (720.6 to 1328.1)
        Opsono-5, PRE(N=48;37)
    16 (11.1 to 23.1)
    25.8 (16.3 to 41)
        Opsono-5, POST(N=47;39)
    143.8 (93.6 to 221)
    243 (151.6 to 389.7)
        Opsono-6B, PRE(N=45;31)
    59.3 (29.3 to 120.1)
    122.7 (50.3 to 299.5)
        Opsono-6B, POST(N=45;40)
    262 (130.3 to 526.5)
    620.3 (356.5 to 1079.4)
        Opsono-7F, PRE(N=49;33)
    819.6 (471.8 to 1423.8)
    1380.6 (730.3 to 2609.9)
        Opsono-7F, POST(N=48;40)
    4199.1 (3364.6 to 5240.6)
    3726.8 (2759.4 to 5033.3)
        Opsono-9V, PRE(N=50;37)
    328.2 (245.4 to 438.8)
    1427 (972.7 to 2093.4)
        Opsono-9V, POST(N=48;38)
    2198 (1718.6 to 2811.1)
    2241.2 (1758.7 to 2856)
        Opsono-14, PRE(N=46;37)
    158.6 (82.6 to 304.6)
    883.8 (597.9 to 1306.2)
        Opsono-14, POST(N=48;40)
    2224.7 (1674.1 to 2956.5)
    1859.4 (1452.1 to 2380.9)
        Opsono-18C, PRE(N=42;33)
    6.5 (4.2 to 10)
    395.9 (219.9 to 712.8)
        Opsono-18C, POST(N=48;38)
    650.3 (437.4 to 966.8)
    1332.9 (926.3 to 1918)
        Opsono-19F, PRE(N=49;38)
    18.7 (12 to 29.3)
    43.3 (23.3 to 80.4)
        Opsono-19F, POST(N=47;38)
    418.4 (237.8 to 736.4)
    513.1 (265.8 to 990.2)
        Opsono-23F, PRE(N=49;34)
    700.6 (376.5 to 1303.9)
    675.8 (293.2 to 1557.4)
        Opsono-23F, POST(N=48;40)
    3594.5 (2676.8 to 4826.8)
    1770 (1148.4 to 2728)
    No statistical analyses for this end point

    Secondary: Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A. (Booster vaccination)

    		 Close Top of page
    End point title
    		 Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A. (Booster vaccination)
    End point description
    OPA titers against pneumococcal serotypes 6A, 19A (Opsono-6A, 19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. Opsonophagocytic activity against cross-reactive pneumococcal serotypes 6A and 19A >= 8. Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.
    End point type
    Secondary
    End point timeframe
    Before and one month after the booster dose with 10Pn for the < 6 months and 7-11 months groups
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    47
    37
    Units: Titer
    geometric mean (confidence interval 95%)
        Opsono-6A, PRE(N=41;33)
    31.9 (15.9 to 63.9)
    140.1 (69.2 to 283.3)
        Opsono-6A, POST(N=43;36)
    188.6 (96.9 to 367)
    302.2 (168.7 to 541.5)
        Opsono-19A, PRE(N=47;35)
    5.7 (4.2 to 7.7)
    7 (3.9 to 12.6)
        Opsono-19A, POST(N=44;37)
    16.1 (8.6 to 30.1)
    36.8 (16.2 to 83.8)
    No statistical analyses for this end point

    Secondary: Antibody concentrations against protein D. (Booster vaccination)

    		 Close Top of page
    End point title
    		 Antibody concentrations against protein D. (Booster vaccination)
    End point description
    Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. Seropositivity = Anti-PD antibody concentrations >= 100 EL.U/mL. Antibody concentrations < 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.
    End point type
    Secondary
    End point timeframe
    Before and one month after the booster dose with 10Pn for the < 6 months and 7-11 months groups
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    140
    114
    Units: EL.U/mL
    geometric mean (confidence interval 95%)
        Anti-PD, PRE(N=140;114)
    750.4 (631.2 to 892)
    563.2 (475.5 to 666.9)
        Anti-PD, POST(N=135;114)
    2900.7 (2481.5 to 3390.8)
    1942 (1614.5 to 2335.9)
    No statistical analyses for this end point

    Secondary: Anti-diphtheria (anti-D) and anti-tetanus toxoids (anti-T) antibody concentrations. (Primary vaccination)

    		 Close Top of page
    End point title
    		 Anti-diphtheria (anti-D) and anti-tetanus toxoids (anti-T) antibody concentrations. (Primary vaccination) [2]
    End point description
    Concentrations of antibodies are presented as geometric mean concentrations expressed as International units per milliliter (IU/mL). Seroprotection status, defined as: Anti-D & anti-T antibody concentrations >=0.1 IU/mL;
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary vaccination course (Month [M]3 = POST-PRY) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group.
    Notes
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only sujects in the 10Pn <6M Group received the InfanrixTM IPV/Hib (DTPa-IPV/Hib) vaccine.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    132
    Units: IU/mL
    geometric mean (confidence interval 95%)
        Anti-D, POST-PRY (N=131)
    0.961 (0.813 to 1.137)
        Anti-T, POST-PRY (N=132)
    2.38 (2.131 to 2.659)
    No statistical analyses for this end point

    Secondary: Anti-polyribosyl ribitol phosphate (PRP) antibody concentrations. (Primary vaccination)

    		 Close Top of page
    End point title
    		 Anti-polyribosyl ribitol phosphate (PRP) antibody concentrations. (Primary vaccination) [3]
    End point description
    Concentrations of antibodies are presented as geometric mean concentrations expressed as micrograms per milliliter (µg/mL). Seroprotection status, defined as: anti-PRP antibody concentrations >=0.15 µg/mL and >= 1.0 µg/mL;
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary vaccination course (Month [M]3 = POST-PRY) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group
    Notes
    [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only sujects in the 10Pn <6M Group received the InfanrixTM IPV/Hib (DTPa-IPV/Hib) vaccine.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    132
    Units: µg/mL
    geometric mean (confidence interval 95%)
        Anti-PRP , POST-PRY (N=132)
    2.886 (2.305 to 3.615)
    No statistical analyses for this end point

    Secondary: Anti-pertussis toxoid (PT), anti-filamentous haemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations. (Primary vaccination)

    		 Close Top of page
    End point title
    		 Anti-pertussis toxoid (PT), anti-filamentous haemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations. (Primary vaccination) [4]
    End point description
    Concentrations of antibodies are presented as geometric mean concentrations expressed as enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). Seropositivity status, defined as: Anti-PT, anti-FHA & anti-PRN antibody concentrations >= 5 EL.U/mL.
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary vaccination course(Month [M]3 = POST-PRY) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group
    Notes
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only sujects in the 10Pn <6M Group received the InfanrixTM IPV/Hib (DTPa-IPV/Hib) vaccine.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    130
    Units: EL.U/mL
    geometric mean (confidence interval 95%)
        Anti-PT, POST-PRY (N=129)
    51.5 (46.5 to 57)
        Anti-FHA, POST-PRY (N=127)
    211.4 (192.7 to 231.8)
        Anti-PRN, POST-PRY (N=130)
    103.2 (90.7 to 117.4)
    No statistical analyses for this end point

    Secondary: Anti-polio type 1, 2 and 3 titers. (Primary vaccination)

    		 Close Top of page
    End point title
    		 Anti-polio type 1, 2 and 3 titers. (Primary vaccination) [5]
    End point description
    Titers of antibodies are presented as geometric mean titers. Seroprotection status, defined as: Anti-polio type 1/2/3 titers >= 8.
    End point type
    Secondary
    End point timeframe
    At 1 month after the administration of the primary vaccination course (Month [M]3 = POST-PRY) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group
    Notes
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only sujects in the 10Pn <6M Group received the InfanrixTM IPV/Hib (DTPa-IPV/Hib) vaccine.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    17
    Units: Titer
    geometric mean (confidence interval 95%)
        Anti-Polio 1, POST-PRY (N=17)
    55.5 (30 to 102.6)
        Anti-Polio 2, POST-PRY (N=16)
    20.2 (9.7 to 41.9)
        Anti-Polio 3, POST-PRY (N=16)
    162.3 (73.5 to 358.5)
    No statistical analyses for this end point

    Secondary: Booster vaccine response to PT, FHA and PRN

    		 Close Top of page
    End point title
    		 Booster vaccine response to PT, FHA and PRN
    End point description
    Booster vaccine response to PT, FHA and PRN, defined as appearance of antibodies in subjects who were seronegative (S-) prior to the booster dose (i.e., with concentrations < 5 EL.U/mL), and at least two-fold increase of pre-booster vaccination antibody concentrations in those who were seropositive (S+) prior to the booster dose (i.e., with concentrations >= 5 EL.U/ mL).
    End point type
    Secondary
    End point timeframe
    one month after the booster dose for the < 6 months Group
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    136
    Units: Subjects
        Anti-PT-Pre-booster status S- (N=14)
    14
        Anti-PT-Pre-booster status S+ (N=121)
    117
        Anti-FHA-Pre-booster status S- (N=0)
    0
        Anti-FHA-Pre-booster status S+ (N=136)
    131
        Anti-PRN-Pre-booster status S- (N=12)
    12
        Anti-PRN-Pre-booster status S+ (N=124)
    123
    No statistical analyses for this end point

    Secondary: Occurrence of solicited local symptoms (any and grade 3). (Primary vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of solicited local symptoms (any and grade 3). (Primary vaccination)
    End point description
    Assessed local symptoms were pain, redness and swelling. Any = Occurrence of the specified solicited local symptom, regardless of intensity. Grade 3 Pain = Crying when limb was moved/spontaneously painful. Grade 3 Redness/Swelling = Redness/swelling at injection site larger than (>) 30 millimeters (mm). Across doses= across the 3 doses (D1, D2 and D3) of the 10Pn-PD-DiT vaccine co-administered with Infranrix™ in the <6 months priming group; across the 2 doses of the 10Pn-PD-DiT vaccine in the 7-11 months priming group; across the 2 doses of the 10Pn-PD-DiT vaccine in the 12-23 months priming group and in the 1 dose of 10Pn-PD-DiT vaccine in the ≥24 months priming group.
    End point type
    Secondary
    End point timeframe
    Within 4-day (Days 0-3) following the primary vaccination
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    149
    148
    149
    148
    Units: Subjects
        Any Pain, D1(N=149;148;149;148)
    63
    52
    93
    102
        Grade 3 Pain, D1(N=149;148;149;148)
    10
    5
    21
    24
        Any Redness, D1(N=149;148;149;148)
    60
    83
    57
    65
        Grade 3 Redness, D1(N=149;148;149;148)
    3
    9
    3
    9
        Any Swelling, D1(N=149;148;149;148)
    37
    48
    39
    32
        Grade 3 Swelling, D1(N=149;148;149;148)
    5
    10
    6
    7
        Any Pain, D2(N=146;147;143;0)
    51
    41
    84
    0
        Grade 3 Pain, D2(N=146;147;143;0)
    0
    0
    12
    0
        Any Redness, D2(N=146;147;143;0)
    66
    70
    52
    0
        Grade 3 Redness, D2(N=146;147;143;0)
    0
    4
    2
    0
        Any Swelling, D2(N=146;147;143;0)
    38
    39
    38
    0
        Grade 3 Swelling, D2(N=146;147;143;0)
    2
    6
    7
    0
        Any Pain, D3(N=145;0;0;0)
    40
    0
    0
    0
        Grade 3 Pain, D3(N=145;0;0;0)
    3
    0
    0
    0
        Any Redness, D3(N=145;0;0;0)
    58
    0
    0
    0
        Grade 3 Redness, D3(N=145;0;0;0)
    1
    0
    0
    0
        Any Swelling, D3(N=145;0;0;0)
    33
    0
    0
    0
        Grade 3 Swelling, D3(N=145;0;0;0)
    2
    0
    0
    0
        Any Pain, Across(N=149;148;149;148)
    89
    63
    113
    102
        Grade 3 Pain, Across(N=149;148;149;148)
    13
    5
    29
    24
        Any Redness, Across(N=149;148;149;148)
    90
    95
    79
    65
        Grade 3 Redness, Across(N=149;148;149;148)
    4
    12
    4
    9
        Any Swelling, Across(N=149;148;149;148)
    68
    66
    59
    32
        Grade 3 Swelling, Across(N=149;148;149;148)
    9
    14
    12
    7
    No statistical analyses for this end point

    Secondary: Occurrence of solicited local symptoms (any and grade 3). (Booster vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of solicited local symptoms (any and grade 3). (Booster vaccination)
    End point description
    Assessed local symptoms were pain, redness and swelling. Any = Occurrence of the specified solicited local symptom, regardless of intensity. Grade 3 Pain = Crying when limb was moved/spontaneously painful. Grade 3 Redness/Swelling = Redness/swelling at injection site larger than (>) 30 millimeters (mm).
    End point type
    Secondary
    End point timeframe
    Within 4-day (Days 0-3) following the booster vaccination
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    144
    145
    Units: Subjects
        Any Pain
    91
    64
        Grade 3 Pain
    11
    3
        Any Redness
    80
    73
        Grade 3 Redness
    11
    5
        Any Swelling
    55
    45
        Grade 3 Swelling
    10
    7
    No statistical analyses for this end point

    Secondary: Occurrence of solicited general symptoms (any and grade 3). (Booster vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of solicited general symptoms (any and grade 3). (Booster vaccination)
    End point description
    Assessed solicited general symptoms were Drowsiness, Irritability, Loss of appetite (Loss Appet.) and Fever (rectal temperature higher than [≥] 38.0 degrees Celsius [°C]),. Any = Occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Irr./Fuss. = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. Grade 3 Fever = Rectal temperature higher than (>) 40.0°C.
    End point type
    Secondary
    End point timeframe
    within 4 day (Days 0-3) following the booster vacination
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    144
    145
    Units: Subjects
        Any Drowsiness
    73
    57
        Grade 3 Drowsiness
    3
    3
        Any Fever (Rectally)
    63
    33
        Grade 3 Fever (Rectally)
    1
    0
        Any Irritability
    109
    71
        Grade 3 Irritability
    5
    3
        Any Loss of Appet.
    57
    35
        Grade 3 Loss of Appet.
    1
    3
    No statistical analyses for this end point

    Secondary: Occurrence of unsolicited adverse events (AEs). (Primary vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of unsolicited adverse events (AEs). (Primary vaccination)
    End point description
    An unsolicited AE was defined as any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For the marketed products administered in the study, this also included failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse of the product. Any = Occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination.
    End point type
    Secondary
    End point timeframe
    within 31-day (Days 0-30) post primary vaccination
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    150
    150
    150
    150
    Units: Subjects
        Any AEs
    100
    116
    101
    54
    No statistical analyses for this end point

    Secondary: Occurrence of unsolicited adverse events (AEs). (Booster vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of unsolicited adverse events (AEs). (Booster vaccination)
    End point description
    An unsolicited AE was defined as any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For the marketed products administered in the study, this also included failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse of the product. Any = Occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination.
    End point type
    Secondary
    End point timeframe
    within 31 day (Days 0-30) following the booster vaccination
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    145
    145
    Units: Subjects
        Any AEs
    90
    63
    No statistical analyses for this end point

    Secondary: Occurrence of serious adverse events (SAEs). (Primary vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of serious adverse events (SAEs). (Primary vaccination)
    End point description
    A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalisation, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE, regardless of relationship to vaccination.
    End point type
    Secondary
    End point timeframe
    during the Primary vaccination course
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    150
    150
    150
    150
    Units: Subjects
        Any SAEs, Primary
    17
    5
    2
    0
    No statistical analyses for this end point

    Secondary: Occurrence of serious adverse events (SAEs). (Booster vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of serious adverse events (SAEs). (Booster vaccination)
    End point description
    A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalisation, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE, regardless of relationship to vaccination.
    End point type
    Secondary
    End point timeframe
    from the End of primary vaccination up to booster vaccination
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group
    Number of subjects analysed
    145
    145
    Units: Subjects
        Any SAEs, Booster
    90
    63
    No statistical analyses for this end point

    Secondary: Occurrence of solicited general symptoms (Primary vaccination)

    		 Close Top of page
    End point title
    		 Occurrence of solicited general symptoms (Primary vaccination)
    End point description
    Assessed solicited general symptoms were Drowsiness, Irritability, Loss of appetite (Loss Appet.) and Fever (rectal temperature higher than [≥] 38.0 degrees Celsius [°C]),. Any = Occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Irr./Fuss. = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. Grade 3 Fever = Rectal temperature higher than (>) 40.0°C. Across doses= across the 3 doses (D1, D2 and D3) of the 10Pn-PD-DiT vaccine co-administered with Infranrix™ in the <6 months priming group; across the 2 doses of the 10Pn-PD-DiT vaccine in the 7-11 months priming group; across the 2 doses of the 10Pn-PD-DiT vaccine in the 12-23 months priming group and in the 1 dose of 10Pn-PD-DiT vaccine in the ≥24 months priming group.
    End point type
    Secondary
    End point timeframe
    Within 4-day (Days 0-3) following the primary vaccination
    End point values
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Number of subjects analysed
    149
    148
    149
    148
    Units: Subjects
        Drowsiness, D1(N=149;148;149;148)
    101
    70
    63
    55
        Grade 3 Drowsiness, D1(N=149;148;149;148)
    2
    1
    1
    1
        Any Fever (Rectally), D1(N=149;148;149;148)
    54
    34
    30
    10
        Grade 3 Fever (Rectally), D1(N=149;148;149;148)
    0
    0
    0
    0
        Any Irritability, D1(N=149;148;149;148)
    122
    90
    90
    62
        Grade 3 Irritability, D1(N=149;148;149;148)
    12
    5
    4
    2
        Any Loss of Appet, D1(N=149;148;149;148)
    45
    42
    46
    41
        Grade 3 Loss of Appet., D1(N=149;148;149;148)
    0
    0
    3
    0
        Any Drowsiness, D2(N=146;147;143;0)
    64
    51
    48
    0
        Grade 3 Drowsiness, D2(N=146;147;143;0)
    0
    0
    2
    0
        Any Fever (Rectally), D2(N=146 ;147;143;0)
    60
    34
    24
    0
        Grade 3 Fever (Rectally), D2(N=146;147;143;0)
    0
    0
    0
    0
        Any Irritability, D2(N=146;147;143;0)
    103
    78
    62
    0
        Grade 3 Irritability, D2(N=146;147;143;0)
    2
    0
    3
    0
        Any Loss of Appet., D2(N=146;147;143;0)
    31
    35
    31
    0
        Grade 3 Loss of Appet., D2(N=146;147;143;0)
    0
    0
    1
    0
        Any Drowsiness, D3(N=145;0;0;0)
    53
    0
    0
    0
        Grade 3 Drowsiness, D3(N=145;0;0;0)
    0
    0
    0
    0
        Any Fever (Rectally), D3(N=145 ;0;0;0)
    40
    0
    0
    0
        Grade 3 Fever (Rectally), D3(N=145;0;0;0)
    0
    0
    0
    0
        Any Irritability, D3(N=145;0;0;0)
    83
    0
    0
    0
        Grade 3 Irritability, D3(N=145;0;0;0)
    3
    0
    0
    0
        Any Loss of Appet., D3(N=145;0;0;0)
    22
    0
    0
    0
        Grade 3 Loss of Appet., D3(N=145;0;0;0)
    0
    0
    0
    0
        Any Drowsiness, Across(N=149;148;149;148)
    122
    92
    90
    55
        Grade 3 Drowsiness, Across(N=149;148;149;148)
    2
    1
    3
    1
        Any Fever (Rectally), Across(N=149;148;149;148)
    95
    55
    47
    10
        Grade 3 Fever (Rectally),Across(N=149;148;149;148)
    0
    0
    0
    0
        Any Irritability, Across(N=149;148;149;148)
    143
    112
    107
    62
        Grade 3 Irritability, Across(N=149;148;149;148)
    16
    5
    7
    2
        Any Loss of Appet., Across(N=149;148;149;148)
    70
    62
    62
    41
        Grade 3 Loss of Appet., Across(N=149;148;149;148)
    0
    0
    4
    0
    No statistical analyses for this end point

    Secondary: Anti-diphtheria (anti-D) and anti-tetanus toxoids (anti-T) antibody concentrations.(Booster vaccination)

    		 Close Top of page
    End point title
    		 Anti-diphtheria (anti-D) and anti-tetanus toxoids (anti-T) antibody concentrations.(Booster vaccination)
    End point description
    Concentrations of antibodies are presented as geometric mean concentrations expressed as International units per milliliter (IU/mL). Seroprotection status, defined as: Anti-D & anti-T antibody concentrations >= 0.1 IU/mL.
    End point type
    Secondary
    End point timeframe
    Before (M9 = PRE-BST) and one month after the booster dose (M10 = POST-BST) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    140
    Units: IU/mL
    geometric mean (confidence interval 95%)
        Anti-D, PRE-BST (N=140)
    0.218 (0.185 to 0.258)
        Anti-D, POST-BST (N=137)
    4.093 (3.578 to 4.683)
        Anti-T, PRE-BST (N=140)
    0.708 (0.616 to 0.813)
        Anti-T, POST-BST (N=137)
    10.245 (9.302 to 11.283)
    No statistical analyses for this end point

    Secondary: Anti-polyribosyl ribitol phosphate (PRP) antibody concentrations. (Booster vaccination)

    		 Close Top of page
    End point title
    		 Anti-polyribosyl ribitol phosphate (PRP) antibody concentrations. (Booster vaccination)
    End point description
    Concentrations of antibodies are presented as geometric mean concentrations expressed as micrograms per milliliter (µg/mL). Seroprotection status, defined as: anti-PRP antibody concentrations >= 0.15 µg/mL and >= 1.0 µg/mL;
    End point type
    Secondary
    End point timeframe
    Before (M9 = PRE-BST) and one month after the booster dose (M10 = POST-BST) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    140
    Units: µg/mL;
    geometric mean (confidence interval 95%)
        Anti-PRP, PRE-BST (N=140)
    0.458 (0.366 to 0.573)
        Anti-PRP, POST-BST (N=136)
    21.244 (16.778 to 26.9)
    No statistical analyses for this end point

    Secondary: Anti-pertussis toxoid (PT), anti-filamentous haemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations. (Booster vaccination)

    		 Close Top of page
    End point title
    		 Anti-pertussis toxoid (PT), anti-filamentous haemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations. (Booster vaccination)
    End point description
    Concentrations of antibodies are presented as geometric mean concentrations expressed as enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). Seropositivity status, defined as: Anti-PT, anti-FHA & anti-PRN antibody concentrations >=5 EL.U/mL.
    End point type
    Secondary
    End point timeframe
    Before (M9 = PRE-BST) and one month after the booster dose (M10 = POST-BST) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    140
    Units: EL.U/mL
    geometric mean (confidence interval 95%)
        Anti-PT, PRE-BST (N=140)
    11.2 (9.8 to 12.7)
        Anti-PT, POST-BST (N=136)
    88.6 (79.5 to 98.7)
        Anti-FHA, PRE-BST (N=140)
    49.2 (43.3 to 55.9)
        Anti-FHA, POST-BST (N=137)
    407.1 (368.5 to 449.8)
        Anti-PRN, PRE-BST (N=140)
    17.2 (14.7 to 20.1)
        Anti-PRN, POST-BST (N=137)
    276.6 (240.9 to 317.6)
    No statistical analyses for this end point

    Secondary: Titers of antibodies against polio type 1, 2 and 3 (Anti-polio 1, 2 and 3). (Booster vaccination)

    		 Close Top of page
    End point title
    		 Titers of antibodies against polio type 1, 2 and 3 (Anti-polio 1, 2 and 3). (Booster vaccination)
    End point description
    Titers of antibodies are presented as geometric mean titers. Seroprotection status, defined as: Anti-polio type 1/2/3 titers >= 8
    End point type
    Secondary
    End point timeframe
    Before (M9 = PRE-BST) and one month after the booster dose (M10 = POST-BST) with DTPa-IPV/Hib vaccine when co-administered with 10Pn, for the < 6 months Group.
    End point values
    		 10Pn <6M Group
    Number of subjects analysed
    18
    Units: Titer
    geometric mean (confidence interval 95%)
        Anti-Polio 1, PRE-BST (N=16)
    19.1 (10.4 to 34.9)
        Anti-Polio 1, POST-BST (N=13)
    617 (302.3 to 1259.2)
        Anti-Polio 2, PRE-BST (N=18)
    14 (7.6 to 25.7)
        Anti-Polio 2, POST-BST (N=13)
    498.5 (198.1 to 1254.3)
        Anti-Polio 3, PRE-BST (N=18)
    20.1 (10.6 to 38.2)
        Anti-Polio 3, POST-BST (N=13)
    1234.1 (688.3 to 2212.4)
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited & Unsolicited AEs: During the 4 & 31 days post PRI/BST vaccination; SAEs: during PRI and BST Phases. The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.
    Adverse event reporting additional description
    Note that 1) SAEs for PRI Phase for 10Pn <6M & 10Pn 7-11M groups include SAEs reported up to BST dose not included; 2) BST Phase safety follow-up is not applicable to 10Pn 12-23M & 10Pn >=24M groups; to mark this, numbers of subjects for BST events for these groups are marked as equal to 1.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    11.0
    Reporting groups
    Reporting group title
    10Pn <6M Group
    Reporting group description
    		 This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of 10Pn-PD-DiT (or 10Pn) vaccine co-administered with InfanrixTM IPV/Hib (DTPa-IPV/Hib) at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (10Pn-PD-DiT) or the left (DTPa-IPV/Hib) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn 7-11M Group
    Reporting group description
    		 This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn 12-23M Group
    Reporting group description
    		 This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of 10Pn-PD-DiT (10Pn), one first dose at enrolment followed by a second dose 2 months later. The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Reporting group title
    10Pn >=24M Group
    Reporting group description
    		 This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of 10Pn-PD-DiT (10Pn). The 10PN-PD-DiT vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).

    Serious adverse events
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    17 / 150 (11.33%)
    5 / 150 (3.33%)
    2 / 150 (1.33%)
    0 / 150 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    Gastrointestinal disorders
    Abdominal pain upper - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 150 (0.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Bronchitis chronic - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 150 (1.33%)
    1 / 150 (0.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Psychomotor retardation - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 150 (0.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 150 (1.33%)
    2 / 150 (1.33%)
    2 / 150 (1.33%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis acute - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 150 (2.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 150 (0.67%)
    2 / 150 (1.33%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis rotavirus - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 150 (2.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis media - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 150 (0.00%)
    2 / 150 (1.33%)
    1 / 150 (0.67%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Exanthema subitum - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 150 (0.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 150 (0.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory syncytial virus bronchiolitis - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 150 (0.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory syncytial virus infection - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 150 (0.67%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacterial infection - BST
    alternative assessment type: Non-systematic
         subjects affected / exposed [1]
    1 / 145 (0.69%)
    0 / 145 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis - BST
    alternative assessment type: Non-systematic
         subjects affected / exposed [2]
    0 / 145 (0.00%)
    1 / 145 (0.69%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 10Pn <6M Group 10Pn 7-11M Group 10Pn 12-23M Group 10Pn >=24M Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    143 / 150 (95.33%)
    116 / 150 (77.33%)
    113 / 150 (75.33%)
    102 / 150 (68.00%)
    General disorders and administration site conditions
    Pain - PRI
         subjects affected / exposed [3]
    89 / 149 (59.73%)
    63 / 148 (42.57%)
    113 / 149 (75.84%)
    102 / 148 (68.92%)
         occurrences all number
    89
    63
    113
    102
    Redness - PRI
         subjects affected / exposed [4]
    90 / 149 (60.40%)
    95 / 148 (64.19%)
    79 / 149 (53.02%)
    65 / 148 (43.92%)
         occurrences all number
    90
    95
    79
    65
    Swelling - PRI
         subjects affected / exposed [5]
    68 / 149 (45.64%)
    66 / 148 (44.59%)
    59 / 149 (39.60%)
    32 / 148 (21.62%)
         occurrences all number
    68
    66
    59
    32
    Drowsiness – PRI Phase
         subjects affected / exposed [6]
    122 / 149 (81.88%)
    92 / 148 (62.16%)
    90 / 149 (60.40%)
    55 / 148 (37.16%)
         occurrences all number
    122
    92
    90
    55
    Rectal fever >= 38.5°C – PRI Phase
         subjects affected / exposed [7]
    95 / 149 (63.76%)
    55 / 148 (37.16%)
    47 / 149 (31.54%)
    10 / 148 (6.76%)
         occurrences all number
    95
    55
    47
    10
    Irritability – PRI Phase
         subjects affected / exposed [8]
    143 / 149 (95.97%)
    112 / 148 (75.68%)
    107 / 149 (71.81%)
    62 / 148 (41.89%)
         occurrences all number
    143
    112
    107
    62
    Loss of appetite – PRI Phase
         subjects affected / exposed [9]
    70 / 149 (46.98%)
    62 / 148 (41.89%)
    62 / 149 (41.61%)
    41 / 148 (27.70%)
         occurrences all number
    70
    62
    62
    41
    Pain – BST
         subjects affected / exposed [10]
    91 / 144 (63.19%)
    64 / 144 (44.44%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    91
    64
    0
    0
    Redness – BST
         subjects affected / exposed [11]
    80 / 144 (55.56%)
    73 / 144 (50.69%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    80
    73
    0
    0
    Swelling – BST
         subjects affected / exposed [12]
    55 / 144 (38.19%)
    45 / 144 (31.25%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    55
    45
    0
    0
    Drowsiness – BST
         subjects affected / exposed [13]
    73 / 144 (50.69%)
    57 / 144 (39.58%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    73
    57
    0
    0
    Rectal fever >= 38.5°C – BST
         subjects affected / exposed [14]
    63 / 144 (43.75%)
    33 / 144 (22.92%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    63
    33
    0
    0
    Irritability – BST
         subjects affected / exposed [15]
    109 / 144 (75.69%)
    71 / 144 (49.31%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    109
    71
    0
    0
    Loss of appetite – BST
         subjects affected / exposed [16]
    57 / 144 (39.58%)
    35 / 144 (24.31%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    57
    35
    0
    0
    Injection site induration - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    10 / 150 (6.67%)
    10 / 150 (6.67%)
    12 / 150 (8.00%)
    1 / 150 (0.67%)
         occurrences all number
    10
    10
    12
    1
    Pyrexia - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    11 / 150 (7.33%)
    21 / 150 (14.00%)
    19 / 150 (12.67%)
    8 / 150 (5.33%)
         occurrences all number
    11
    21
    19
    8
    Pyrexia - BST
    alternative assessment type: Non-systematic
         subjects affected / exposed [17]
    8 / 145 (5.52%)
    12 / 145 (8.28%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    8
    12
    0
    0
    Eye disorders
    Conjunctivitis - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    6 / 150 (4.00%)
    12 / 150 (8.00%)
    4 / 150 (2.67%)
    2 / 150 (1.33%)
         occurrences all number
    6
    12
    4
    2
    Gastrointestinal disorders
    Diarrhoea - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    6 / 150 (4.00%)
    14 / 150 (9.33%)
    14 / 150 (9.33%)
    5 / 150 (3.33%)
         occurrences all number
    6
    14
    14
    5
    Teething - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    9 / 150 (6.00%)
    17 / 150 (11.33%)
    4 / 150 (2.67%)
    0 / 150 (0.00%)
         occurrences all number
    9
    17
    4
    0
    Respiratory, thoracic and mediastinal disorders
    Cough - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 150 (3.33%)
    15 / 150 (10.00%)
    20 / 150 (13.33%)
    5 / 150 (3.33%)
         occurrences all number
    5
    15
    20
    5
    Infections and infestations
    Nasopharyngitis - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 150 (0.00%)
    0 / 150 (0.00%)
    11 / 150 (7.33%)
    0 / 150 (0.00%)
         occurrences all number
    0
    0
    11
    0
    Otitis media - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    6 / 150 (4.00%)
    24 / 150 (16.00%)
    21 / 150 (14.00%)
    10 / 150 (6.67%)
         occurrences all number
    6
    24
    21
    10
    Rhinitis - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    19 / 150 (12.67%)
    31 / 150 (20.67%)
    18 / 150 (12.00%)
    4 / 150 (2.67%)
         occurrences all number
    19
    31
    18
    4
    Upper respiratory tract infection - PRI
    alternative assessment type: Non-systematic
         subjects affected / exposed
    40 / 150 (26.67%)
    35 / 150 (23.33%)
    21 / 150 (14.00%)
    7 / 150 (4.67%)
         occurrences all number
    40
    35
    21
    7
    Otitis media - BST
    alternative assessment type: Non-systematic
         subjects affected / exposed [18]
    13 / 145 (8.97%)
    8 / 145 (5.52%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    13
    8
    0
    0
    Ear infection - BST
    alternative assessment type: Non-systematic
         subjects affected / exposed [19]
    0 / 145 (0.00%)
    9 / 145 (6.21%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    9
    0
    0
    Rhinitis - BST
    alternative assessment type: Non-systematic
         subjects affected / exposed [20]
    24 / 145 (16.55%)
    8 / 145 (5.52%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    24
    8
    0
    0
    Upper respiratory tract infection - BST
    alternative assessment type: Non-systematic
         subjects affected / exposed [21]
    25 / 145 (17.24%)
    12 / 145 (8.28%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    25
    12
    0
    0
    Notes
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [15] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [16] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [17] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [18] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [19] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [20] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results
    [21] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Assessment for this event for this phase was performed solely on subjects with available results

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    28 Jun 2006
    The protocol was amended to clarify in the study title that the assessment of immunogenicity, safety and reactogenicity would be done in children older than 7 months of age and in children before 6 months of age. Furthermore, because the post-licensure surveillance of Prevenar in the United States had shown a decrease and an increase in invasive pneumococcal disease caused by the cross-reactive pneumococcal serotypes 6A and 19A, respectively, it was of interest to document the immune responses (Enzyme-Linked Immuno-Sorbent Assay [ELISA] and opsonophagocytic activity [OPA]) to these cross-reactive pneumococcal serotypes. Also a higher flexibility of the distribution of replacement vial/syringe for the 10Pn-PD-DiT vaccine at the study centres was allowed as in each group all the children would receive the same vaccine.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 21:19:10 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA